[go: up one dir, main page]

KR960703588A - 인간의 성적 감응을 조절하는 방법(methods for modulation the human sexual response) - Google Patents

인간의 성적 감응을 조절하는 방법(methods for modulation the human sexual response) Download PDF

Info

Publication number
KR960703588A
KR960703588A KR1019960700714A KR19960700714A KR960703588A KR 960703588 A KR960703588 A KR 960703588A KR 1019960700714 A KR1019960700714 A KR 1019960700714A KR 19960700714 A KR19960700714 A KR 19960700714A KR 960703588 A KR960703588 A KR 960703588A
Authority
KR
South Korea
Prior art keywords
sexual response
medicament
methods
modulation
drug
Prior art date
Application number
KR1019960700714A
Other languages
English (en)
Other versions
KR100391025B1 (ko
Inventor
아드리안 더블유. 조르그니오티
다이앤-마리 지오코
Original Assignee
죠셉 에스. 포돌스키
조나겐, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22311403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960703588(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 죠셉 에스. 포돌스키, 조나겐, 인코오포레이티드 filed Critical 죠셉 에스. 포돌스키
Publication of KR960703588A publication Critical patent/KR960703588A/ko
Application granted granted Critical
Publication of KR100391025B1 publication Critical patent/KR100391025B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Control Of Fluid Pressure (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 "1차-통과" 효과를 배제하는 투여 경로에 의해 순환계로 혈관확장제를 투여함으로써, 인간의 성적 감응을 조절하는 개선된 방법에 관한 것이다.

Description

인간의 성적 감응을 조절하는 방법(METHODS FOR MODULATING THE HUMAN SEXUAL RESPONSE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 20mg 용량의 펜톨아민 메실레이트를 협측 투여한 후 음경의 동맥혈 속도에 대한 변화율을 도시한 그래프이다.

Claims (5)

  1. 인간의 성적 감응을 조절하기 위한 목적의, 경점막, 경피, 비강내 및 직장 투여용 약제를 제조하는데 혈관확장 활성을 가진 약물을 사용하는 방법.
  2. 제1항에 있어서, 상기 약물이 펜톨아민 메실레이트, 펜톨아민 하이드로클로라이드, 페녹시벤즈아민, 요힘빈, 니트로글리세린, 티목스아민, 이미프라민, 베라파밀, 이속스수프린, 나프티드로푸릴, 톨라졸린 및 파파베린으로 이루어진 군중에서 선택된 것임을 특징으로 하는 사용 방법.
  3. 남성의 발기불능을 치료하기 위한 목적의, 경점막 투여용 약제를 제조하는데 펜톨아민 메실레이트를 함유한 약물을 사용하는 방법.
  4. 제3항에 있어서, 상기 약제가 정제형인 것을 특징으로 하는 사용 방법.
  5. 제4항에 있어서, 상기 각 정제가 약 5mg 내지 약 80mg의 펜톨아민 메실레이트를 함유하는 것을 특징으로 하는 사용 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700714A 1993-08-13 1994-08-10 인간의성적감응을조절하는방법 KR100391025B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10643493A 1993-08-13 1993-08-13
US08106434 1993-08-13
US08/106,434 1993-08-13

Publications (2)

Publication Number Publication Date
KR960703588A true KR960703588A (ko) 1996-08-31
KR100391025B1 KR100391025B1 (ko) 2003-10-04

Family

ID=22311403

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700714A KR100391025B1 (ko) 1993-08-13 1994-08-10 인간의성적감응을조절하는방법

Country Status (16)

Country Link
US (1) US5565466A (ko)
EP (1) EP0714300B1 (ko)
JP (1) JP3782101B2 (ko)
KR (1) KR100391025B1 (ko)
CN (1) CN1103589C (ko)
AT (1) ATE174795T1 (ko)
BR (1) BR9407250A (ko)
CA (1) CA2169071C (ko)
DE (1) DE69415535T2 (ko)
DK (1) DK0714300T3 (ko)
ES (1) ES2127409T3 (ko)
GR (1) GR3029500T3 (ko)
NO (1) NO311785B1 (ko)
NZ (1) NZ271567A (ko)
WO (1) WO1995005172A1 (ko)
ZA (1) ZA946123B (ko)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
FR2748658B1 (fr) * 1996-05-15 2000-08-18 Biotec Centre Sa Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique
AU3823597A (en) * 1996-08-09 1998-03-06 Urometrics, Inc. Male impotence diagnostic ultrasound system
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
BR9809848A (pt) * 1997-05-19 2000-06-27 Zonagen Inc Composição
ATE315931T1 (de) * 1997-06-23 2006-02-15 Cellegy Pharma Inc Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
EP1535611A3 (en) * 1997-06-23 2009-09-16 Strakan International Limited Microdose therapy of vascular conditions by no donors
FR2765483B1 (fr) * 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
JP2001509480A (ja) 1997-07-09 2001-07-24 アンドロソリューションズ，インク． 男性勃起機能不全を治療するための改良された方法及び組成物
US6251076B1 (en) 1997-08-01 2001-06-26 Urometrics Inc. Male impotence diagnostic ultrasound system
US5947901A (en) 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5879665A (en) * 1997-09-25 1999-03-09 The Board Of Regents Of The University Of Oklahoma Composition for causing skin lightening
US6110448A (en) * 1997-09-25 2000-08-29 The Board Of Regents Of The University Of Oklahoma Method for causing skin lightening
US5919436A (en) * 1997-09-25 1999-07-06 The Board Of Regents Of The University Of Oklahoma Method of lightening skin
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
AUPP010397A0 (en) * 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
TW380045B (en) 1998-01-13 2000-01-21 Urometrics Inc Devices and methods for monitoring female arousal
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
GB9802078D0 (en) * 1998-01-30 1998-03-25 Futura Medical Limited Preparation for treatment of erectile dysfunction
FR2774593B1 (fr) * 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
FR2774594A1 (fr) * 1998-02-12 1999-08-13 Philippe Gorny Medicament destine notamment a prevenir ou traiter les dysfonctions erectiles
US6365590B1 (en) 1998-05-26 2002-04-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
CA2340206A1 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti-pressor agents for vascular remodeling in genital dysfunction
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
BR0009583A (pt) * 1999-04-06 2002-06-11 Zonagen Inc Métodos para modular a resposta sexual em um ser humano, e para a manufatura de um medicamento para modular a resposta sexual em um ser humano
US6214849B1 (en) 1999-04-29 2001-04-10 Lupin Laboratories Limited Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6405219B2 (en) 1999-06-22 2002-06-11 F5 Networks, Inc. Method and system for automatically updating the version of a set of files stored on content servers
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6762202B2 (en) 2000-05-09 2004-07-13 Nitromed, Inc. Infrared thermography and methods of use
US20040137081A1 (en) * 2003-01-13 2004-07-15 Peter Rohdewald Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
EP1328281B1 (en) 2000-06-27 2007-08-15 Qualilife Pharmaceuticals Inc. Compositions and methods for treating females sexual response
FI20002755A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US20030158184A1 (en) * 2001-12-21 2003-08-21 Garvey David S. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU2005239962B2 (en) 2004-05-11 2011-07-07 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
CA2776426C (en) * 2008-10-10 2019-01-15 Milux Holding S.A. Stimulation of penis erection
US8939889B1 (en) 2013-08-22 2015-01-27 Coloplast A/S Pump bulb for an implantable penile prosthetic
EP3220812B1 (en) * 2014-11-17 2023-10-25 David A. Borkholder Pulse wave velocity, arterial compliance, and blood pressure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943246A (en) * 1972-07-10 1976-03-09 Sandoz Ltd. Organic compounds
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
WO1990015583A1 (en) * 1989-06-16 1990-12-27 Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki Device for treating sexual weakness in men
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence

Also Published As

Publication number Publication date
JPH09501677A (ja) 1997-02-18
AU7523894A (en) 1995-03-14
CA2169071A1 (en) 1995-02-23
EP0714300B1 (en) 1998-12-23
ZA946123B (en) 1995-03-20
US5565466A (en) 1996-10-15
DK0714300T3 (da) 1999-08-23
AU696815B2 (en) 1998-09-17
WO1995005172A1 (en) 1995-02-23
DE69415535T2 (de) 1999-06-17
CA2169071C (en) 2008-10-21
KR100391025B1 (ko) 2003-10-04
DE69415535D1 (de) 1999-02-04
ATE174795T1 (de) 1999-01-15
NO960549L (no) 1996-04-12
NZ271567A (en) 1997-12-19
EP0714300A4 (en) 1996-07-24
EP0714300A1 (en) 1996-06-05
BR9407250A (pt) 1996-09-24
GR3029500T3 (en) 1999-05-28
NO311785B1 (no) 2002-01-28
CN1128950A (zh) 1996-08-14
JP3782101B2 (ja) 2006-06-07
NO960549D0 (no) 1996-02-12
CN1103589C (zh) 2003-03-26
ES2127409T3 (es) 1999-04-16

Similar Documents

Publication Publication Date Title
KR960703588A (ko) 인간의 성적 감응을 조절하는 방법(methods for modulation the human sexual response)
BRPI0410542A (pt) dispositivo de administração de medicamento para um olho e método de administrar um agente farmaceuticamente ativo a um olho
KR910009243A (ko) 치근막 질환 치료용 서방성 조성물
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
NL189898C (nl) Vaste, farmaceutische doseringsvorm voor de orale toediening alsmede werkwijze ter vervaardiging daarvan.
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
NL7700578A (nl) Gesubstitueerde n-fenyl-n'-benzoylurea, een werkwijze voor de bereiding daarvan en de toe- passing als insekticide.
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
KR890011585A (ko) 경피식 피임약제제형
DE3787377D1 (de) Eindringungserhöhende mittel zur transdermalen verabreichung systemischer mittel.
ATE251901T1 (de) Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
DK0538302T3 (da) Reduktion eller forhindring af hudirritation forårsaget af lægemidler
NL7704444A (nl) Zuiglichaam voor hygienische toepassingen, alsmede werkwijze voor de vervaardiging daarvan.
DK0502092T3 (da) Oralt præparat til behandling af inflammatoriske tarmsygdomme
ATE62414T1 (de) Mittel zur behandlung von herzerkrankungen.
DK373187A (da) Laegemiddel med langsom frigivelse af den aktive bestanddel
CY1115064T1 (el) Διαδερμικο συστημα παραδοσης ορμονων χωρις ενισχυτες διεισδυσης
KR880012227A (ko) 도파민 수용체 길항제의 신규사용법
ATE292453T1 (de) Antivirale arznei
NL930071I1 (nl) Werkwijze voor het bereiden van delta15-steroïden werkwijze voor het bereiden of vervaardigen van een geneesmiddel met gestagene werking en gevormd geneesmiddel
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
KR880010765A (ko) 니트로글리세린의 경피 투여형 약제
ES2036661T3 (es) Un metodo para preparar una preparacion farmaceutica de pie de atleta.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990806

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010925

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20020430

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20010925

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20020801

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20020430

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20030416

Appeal identifier: 2002101003008

Request date: 20020801

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20020830

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20020830

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20020801

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20011126

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19990806

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20021028

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20030416

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20021001

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20030630

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20030701

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20060626

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20070413

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20080414

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20090415

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20100531

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20110420

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20120608

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20120608

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20130612

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20130612

Start annual number: 11

End annual number: 11

PC1801 Expiration of term

Termination date: 20150210

Termination category: Expiration of duration